ALBUQUERQUE, N.M.–(BUSINESS WIRE)– #ai–VisionQuest Biomedical Inc. announces that it has been awarded a $2M grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to commercialize ASPIRE, a device that uses artificial intelligence (AI) to improve the diagnosis of cerebral malaria. Every year, up to 100,000 children in Africa die from cerebral malaria. Up to a third of fatal cases could be prevented by a more accurate diagnosis of the disease. ASPIRE in